Setting up pharmacovigilance based on available endTB Project data for bedaquiline

Lachenal N.; Hewison C.; Mitnick C.; Lomtadze N.; Coutisson S.; Osso E.; Ahmed S.; Leblanc G.; Islam S.; Atshemyan H.; Nair P.; Kholikulov B.; Aiylchiev S.; Zarli K.; Adnan S.; Krisnanda A.; Padayachee S.; Stambekova A.; Sahabutdinova Y.; de Guadalupe Perea Moreno S.; Kumsa A.; Reshid A.; Makaka J.; Abebe S.; Melikyan N.; Seung K.J.; Khan U.; Khan P.; Huerga H.; Rich M.; Varaine F. · International Journal of Tuberculosis and Lung Disease (2020) · DOI: 10.5588/ijtld.20.0115

Resumen

SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNITAID in April 2015, endTB (Expand New Drug markets for TB) facilitated treatment with bedaquiline (BDQ) and/or delamanid of.2600 patients in 17 countries, and contributed to the creation of a central PV unit (PVU). OBJECTIVE: To explain the endTB PVU process by describing the serious adverse events (SAEs) experienced by patients who received BDQ-containing regimens. DESIGN: The overall PV strategy was in line with the 'advanced' WHO active TB drug safety monitoring and management (aDSM) system. All adverse events (AEs) of clinical significance were followed up; the PVU focused on signal detection from SAEs. RESULTS AND CONCLUSION: Between 1 April 2015 and 31 March 2019, the PVU received and assessed 626 SAEs experienced by 417 BDQ patients. A board of MDR-TB/PV experts reviewed unexpected and possibly drug-related SAEs to detect safety signals. The experts communicated on clusters of risks factors, notably polypharmacy and off-label drug use, encouraging a patient-centred approach of care. Organising advanced PV in routine care is possible but demanding. It is reasonable to expect local/national programmes to focus on clinical management, and to limit reporting to aDSM systems to key data, such as the SAEs.